



PRISM

Cancer Science and Targeted Therapy Conference

September 06-08, 2021

Melbourne Cricket Ground
Olympic Room Locked Bag 6 East
Melbourne, 8002, Australia



Cancer Therapy 2021

The meeting aims to bring together the pioneers in both basic and translational cancer research and cover the research studies discovering the genes affect cancer risk and the genomics; fundamentals of cancer cells and the hormone responses, cancer-controlling proteins, cell signaling and growth, novel diagnostic methods, new-generation molecular targeted therapies and immune treatments.

Cancer Therapy 2021 scientific meeting on September 06-08, 2021 at Melbourne

Committee Members



Marco Falasca

Conference Chair
Curtin University
Perth



Kenny Chitcholtan

University of Otago
Christchurch
New Zealand



Ygal Haupt

Peter Mac Callum
Cancer Centre
Melbourne, Australia



Khosrow Kashfi

The City College of
New York
NY, USA



Suresh Ambudkar

NCI/NIH
MD, USA

Scientific Sessions

- ◆ Cancer Metastasis and Biology
- ◆ Targeted Cancer Therapies
- ◆ Cancer Immunotherapies
- ◆ Growth Factor Signalling in Cancer
- ◆ Lipid Signalling in Cancer
- ◆ Extracellular Vesicles in Cancer
- ◆ Cancer Microenvironment
- ◆ Cancer Stem Cells
- ◆ Cancer Genetics and Biomarkers
- ◆ Novel Therapeutics Target For Cancer
- ◆ Cancer Chemotherapy, Resistance and Prevention
- ◆ Breast Cancer
- ◆ Lung Cancer
- ◆ Cancer Epidemiology

Conference Introduction

Session-1 Chemoresistance**To Trick a Transporter: Targeting Lysosomal P-glycoprotein with Innovative Multi-functional Anti- tumour Agents**

Des R. Richardson, University of Sydney, New South Wales, Australia

Cancer Chemoresistance and ABC Drug Transporters

Suresh V. Ambudkar, NCI/NIH, MD, USA

Why do we need to know where drugs bind on P-gp?

Richard Callaghan, The Australian National University, Canberra, Australia

Coffee Break**Session-2** Growth Factor Signalling**c-Met Activation Leads to the Establishment of a TGF β -receptor Regulatory Network Required for Bladder Cancer Invasion**

Pieter Eichhorn, Curtin University, Perth, Australia

Targeting Protein Synthesis and Growth Signalling in Prostate Cancer

Luc Furic, Monash University, Melbourne, Australia

The TWEAK/Fn14 Pathway as a Therapeutic Target in Hepatocellular Carcinoma and Cholangiocarcinoma

Nina Tirnitz-Parker, Curtin Health Innovation Research Institute, Perth, Australia

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors

Kenny Chitcholtan, University of Otago, Christchurch, New Zealand

Lunch Break**Session-3** Lipid Signalling**Targeting Sphingolipid Metabolism in Acute Myeloid Leukemia**

Stuart Pitson, University of South Australia and SA Pathology, Adelaide, Australia

Regulation of Phosphoinositide 3-kinase Signaling in Breast Cancer

Christina Mitchell, Monash University, Melbourne, Australia

Class II Phosphoinositide 3-kinase β and Cancer: A Novel Therapeutic Target?

Tania Maffucci, Queen Mary University of London, UK

Characterising Roles of the PTEN-PI3K Axis in Breast Tumorigenesis

Antonella Papa, Monash University, Melbourne, Australia

Identifying Optimal Strategies to Target S1P Signaling for the Attenuation of Cancer Progression and Chemotherapeutic Toxicity

Deron R. Herr, National University of Singapore, Singapore

Session-4

Extracellular Vesicles

Remote Control of Neuroblastoma Metabolism, Proliferation and Gene Expression through MYCN-Regulated Extracellular Vesicles

Arturo Sala, Brunel University London, UK

Pancreatic Cancer: Perspectives for a Brighter Prognosis

Marco Falasca, Curtin University, Perth, Australia

Exosomes Orchestrate Fibroblast-led Cancer Invasion – New Insights into Cancer Signalling

David Greening, Baker Heart and Diabetes Institute, Melbourne, Australia

Session-5 Novel Therapeutics Target in Cancer

Restoration of Tumour Suppression to Treat wt and Mutant p53 Hormone Related Cancers

Ygal Haupt, Peter MacCallum Cancer Centre, Melbourne, Australia

Functional Genomic Approaches to Identify new Wnt/b-catenin Regulators in Colorectal Cancer

Ron Firestein, Cancer Centre at Hudson Institute, Monash University, Melbourne, Australia

Ophiobolin A: A Promising Antiglioblastoma Agent

Alexander Kornienko, Texas State University, TX, USA

Investigation of miRNA and mRNA Co-expression Network in Ependymoma

Tao Huang, Chinese Academy of Sciences, China

Coffee Break

Session-6 Cancer Immunotherapy

Immune Landscape Sculptured by the Peritoneal Microenvironment that supports Metastases arising from Colorectal Primary Tumours

Robert G. Ramsay, Peter MacCallum Cancer Centre, Melbourne, Australia

Immunotherapy of Solid Tumor with the Third Generation TCR-T

Yi Li, Guangzhou Institutes of Biomedicine and Health, China

Deciphering the Role of CD70/CD27 in Oncology

Julie Jacobs, Scientist, Argenx Inc., Belgium

Cancer Immunotherapy by Targeting TGF-B/Smad3

Guangyu Lian, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

Distribution and Functions of CD39+T δ Tregs Infiltrated in the Microenvironment of Left/Right- Sided Colorectal Cancer

Zhan Yang, Tianjin Medical University Cancer Institute and Hospital, China

Lunch Break

Session-7 Tumor Microenvironment and Cancer Stem Cells

Novel Nanomedicine Shuts Down Metabolic Cellular Cross-talk Which Reduces Fibrosis and Pancreatic Tumour Progression

Phoebe Phillips, Prince of Wales Clinical School, UNSW Medicine NSW, Australia

Targeting Cell-Cell Communication in Tumours and the Tumour Microenvironment

Peter Janes, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Proteomic Profiling of the Prostate Tumour Microenvironment Reveals LOXL2 as a Therapeutic Target

Natalie Lister, Monash University, Melbourne, Australia

The Prognostic Value of S100A10 in Cancer

Normastuti Adhini Tanty, Indonesia International Institute for Life Sciences, Indonesia

Coffee Break

Session-8 Cancer Targeted Therapy

Regulation of the Hypoxia Transcription Factors by Ascorbate and Potential Implications for Cancer Patients

Gabi Dachs, University of Otago, Christchurch, New Zealand

Repurposing Flubendazole as a Small Molecule Inhibitor of Programmed Cell Death Protein-1

Levon M. Khachigian, University of New South Wales, Sydney, Australia

Discovery of Novel Targetable Pathways and Drug Molecules for Infant Acute Lymphoblastic Leukaemia

Klaartje Somers, Children's Cancer Institute, Sydney, Australia

EDNRB Isoform 3 Confers Temozolomide Resistance in Human Melanoma Cells by Modulating Membrane Potential, Reactive Oxygen Species and Mitochondrial Ca²⁺

Long Cui, Guangzhou Women and Children's Medical and The Chinese University of Hong Kong, Hong Kong

Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma

Xuan Zhang, Shandong University, China

Poster Presentations

Session-9

Cancer Genetics

SMAD Proteins Directly Suppress PAX2 Transcription Downstream of Transforming Growth Factor Beta 1 Signalling in Renal Cell Carcinoma

Michael Eccles, University of Otago, Christchurch, New Zealand

Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion

Chiaki Takahashi, Cancer Research Institute, Kanazawa University, Japan

High Methylation of ZNF582/PAX1 in Cervical Cancer Affected Radio-chemo and Neoadjuvant Chemotherapy Sensitivity and Prognosis

Yuligh Liou, Xiangya Medical Laboratory, Central South University, China

Clinical Application of Tube-chip Digital PCR for Accurate Detection of Gene Mutation in Cancer Patients

Xiwen Jiang, DAAN Gene Co., Ltd. of Sun Yat-sen University, China

**Cancer Therapy 2021****Conference Secretariat****Prism Scientific Services Pty Ltd**

Level 14, 380 St Kilda Road, Melbourne, VIC 3004, Australia Tel: +61 383 913 150

Email: manager@cancertherapyconference.com

Web: <https://www.cancertherapyconference.com/>